On January 20, 2022, Metuchen Pharmaceuticals LLC (Metuchen), a wholly owned subsidiary of Petros Pharmaceuticals, Inc. (the Company), entered into a Technology Transfer Service Agreement with Patheon Pharmaceuticals Inc., part of Thermo Fisher Scientific (Patheon) (the Agreement), pursuant to which the parties agreed to collaborate as strategic partners for commercial production of the Company's Stendra® (avanafil) tablets at Patheon's facilities in Cincinnati, Ohio. Under the Agreement, Patheon or one of its affiliates will provide certain pharmaceutical development and technology transfer services in order to establish and validate its ability to manufacture supply of the Company's Stendra® product. Any commercial sale of product manufactured during the performance of the Agreement must be subject to a subsequent commercial manufacturing services agreement (with associated quality agreement) between the parties before it can be offered for commercial sale.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4226 USD | -0.73% |
|
-1.03% | -70.03% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-70.03% | 2.96M | |
+24.74% | 47.54B | |
-0.47% | 41.96B | |
+48.94% | 41.55B | |
+25.40% | 30.36B | |
+17.96% | 27.61B | |
-4.47% | 28.7B | |
+50.73% | 14.7B | |
+42.56% | 13.51B | |
+1.46% | 12.34B |
- Stock Market
- Equities
- PTPI Stock
- News Petros Pharmaceuticals, Inc.
- Petros Pharmaceuticals, Inc. Enters Technology Transfer Service Agreement with Patheon Pharmaceuticals